Renewal, Russian pharmaceutical manufacturer (“PFK Obnovleniie”) has started to produce L-thyroxine, a thyroid gland therapy, in Russia. This is reported by RIA Novosti with reference to Vladimir Grechkin, executive director of the Novosibirsk pharmaceutical company.
“Today, on April 19, Renewal has launched the production of L-thyroxine Renewal. According to production plans and the dates of scheduled delivery from the manufacturer to pharmacies through distributors, we expect the product to appear in pharmacies in the country in early to mid-May,” Grechkin said.
According to him, at the initial stage the production capacity makes it possible to make 500,000 packages of L-thyroxine a month. Later the company will be able to produce up to one million packages per month, if necessary.
Sergey Semka, Deputy Governor of the Novosibirsk region, previously told the media that the pharmaceutical company’s capacity is enough to cover 100% of Russia’s demand for L-thyroxine. Foreign-made drugs of this type currently account for more than 90% of the market.
On April 6, the Ministry of Health of the Russian Federation stated that it had registered the domestic vital drug L-Thyroxine Renewal (INN Levothyroxine Sodium) produced by the Russian pharmaceutical company PFK “Obnovleniie” in two dosage forms: 50 mcg and 100 mcg.
Mikhail Murashko, the Minister of Health of the Russian Federation, reported on the facts of the absence of certain medicines in the country, in particular, Levothyroxine, which is used for thyroid disease. In the first week of March, its sales increased tenfold, and in the second, five times. Patients taking these drugs stocked on them in large quantities. Over the past month, the sales of L-thyroxine and Euthyrox in Russia were five times higher than for the same period a year ago.
